United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$323.88 USD
-5.37 (-1.63%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $323.46 -0.42 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 381 - 400 ( 596 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
November and Remaining 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Our Thoughts on Value Drivers and the Legal Pile-Up on Patent ?393
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Financials: Top and Bottom-Lines Beat on Strong Product Sales; Reiterate OUTPERFORM and $244 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Preview: Consensus Revenues Slightly High but GAAP EPS Beatable In Our View; Reiterate OUTPERFORM and $244 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
A Closer Look at the Sandoz Settlement and its Read-through on Parallel IP Litigation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
September and 2015 Catalysts for Emerging PharmaceuticalsThis report contains brief updates on the following: BIOD, BMRN, CBYL, ICPT, LXRX, OMER, PCRX, RGLS, RLYP, SGMO, UTHR, VTAE, XOMA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals: September and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
$350 Million for Rare Pediatric Disease Voucher Makes Unituxin Highly Profitable, in Our View; Reiterate OUTPERFORM but Increase Price Target to $244
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Unituxin(TM) Granted Market Authorization by the European Commission; Reiterate OUTPERFORM and $209 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
August and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L